In the field of therapeutic antibody development, Creative Biolabs has an increasing accumulation of experience and has already provided numerous comprehensive services and high-quality products for our clients all over the world. Recently we complete our list of agonistic antibody to be used in therapy-related and antibody-based researches.
Since the first application in cancer therapy, monoclonal antibody (MAb) is shown of promising therapeutic effect. In spite of classical mechanism of actions exerted by MAb, such as neutralization, blocking, CDC, ADCC, therapeutic antibody could also act as agonists of the receptors, essentially replacing the activity of the normal ligand. The agonist activity can occur when the antibody binds the receptor in a manner that mimics the binding of the physiological ligand resulting in antibody-mediated agonism. To date, much of the agonistic antibody in clinical and pre-clinical studies target TNF family members, such as OX40, CD27, 4-1BB and DR5. Specifically, there are currently at least 11 therapeutic antibodies in clinical trials which are intended to function as agonists, for example anti-CD40 antibody, CP-870893 from Pfizer, anti-DR5 antibody, Conatumumab from Amgen, and anti-GITR antibody, TRX518 from Tolerx.
To meet the need in study of therapeutic antibody of various mechanisms of actions, especially agonism, scientists in Creative Biolabs dedicated to developing the best-in-all antibody products for our clients. A list of our agonistic antibody product is presented to refer.
|Target||Catalog No.||Target||Catalog No.||Target||Catalog No.|
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us